P0089 Combination of curcumol with celecoxib synergistically enhances their anti-migration effects via FAK/ERK/PI3K/AKT pathways in human non-small-lung cancer cells

Abstract

Background Celecoxib, a COX-2 inhibitor, may be a potent chemopreventive agent for lung cancer. However, the long-term use of celecoxib is not safe and may be limited due to its serious side-effects. Methods We examined the effect of curcumol, a common traditional Chinese medicine isolated from Rhizoma curcumae, on the inhibitory potential of celecoxib in human non-small-cell lung cancer cells. Findings Our data suggest a synergistic interaction between curcumol and celecoxib in terms of lung cancer cell growth inhibition, without enhanced toxicity in normal human cells (HUVEC). The combination of curcumol and celecoxib was not able to close the wound area in a wound healing assay. Mediation of the enhanced inhibitory efficacy in lung cancer cells was achieved by reducing tumour cell migration and was closely associated with the deregulation of focal adhesion proteins (FAK), and phosphorylation of ERK and PI3K. Interpretation These data demonstrate that combined medication involving curcumol and celecoxib could be effective for anti-migration in the treatment of lung cancer cells.